Blog

DEEP RESEARCH · HLB

HLB: Integrated Company, Professional Management, and the Third FDA Attempt

A single investment narrative around the HLB Science merger, governance reset, rivoceranib CMC remediation, and LMR funding.

Date: 2025-12-31 · Biotech/governance/FDA approval lens · Source: Original Naver Blog post

Investment decisions are your own responsibility. This material is research and is not a buy or sell recommendation.

0. Bottom line first

My conclusion is that HLB's late-2025 changes are not merely personnel and merger events. They are a redesign of the business structure before another FDA attempt. The HLB Science merger integrated pipeline and financial risk, while Jin Yang-gon's move to board chair and the professional management appointments distributed execution responsibility. The key variables are the planned January 2026 resubmission and the FDA decision expected around July.

Integrated HLB and HLB Science structure image

1. Merger: combining R&D and finance into One HLB

Official fact: The source says that on December 31, 2025, HLB officially launched an integrated HLB by absorbing subsidiary HLB Science. The merger ratio is 1 : 0.0446318, and the source says a small-scale merger procedure was used because newly issued shares were about 0.6% of total shares.

The small-scale merger structure matters for speed and cash-flow control. Under Korean Commercial Act rules described in the source, if new shares issued by the surviving company after merger do not exceed 10% of total outstanding shares, board approval can replace a shareholders' meeting. HLB shareholders do not receive appraisal rights. HLB Science shareholders do, but the source expects the actual exercise scale to be limited.

CategoryPre-merger HLBPre-merger HLB ScienceIntegrated HLB
Main fieldOncology, rivoceranibInfectious disease, sepsis, degenerative brain diseaseOncology + CNS + Infectious Disease
Clinical stageNDA preparation, near commercializationPhase 1, preclinicalFull-cycle pipeline
Financial positionCan raise large capital, has liquidityCapital impairment concerns, funding difficultyFinancial stability and investment efficiency
Organizational efficiencyDuplicate admin functionsDuplicate admin functionsShared functions and fixed-cost reduction

Interpretation: HLB Science's DD-S052P and DD-A279 provide options to reduce oncology concentration. Combined with HLB's global phase 3, NDA, and regulatory affairs experience, early-stage pipelines gain clinical and approval capability.

2. Portfolio: beyond oncology into infection and neurology

Rivoceranib

Core first-line liver cancer asset

The pipeline representing HLB's global commercialization possibility and the center of the FDA resubmission.

DD-S052P

Sepsis and gram-negative bacteria therapy

The source describes it as a drug with a dual mechanism of bacterial killing and endotoxin neutralization, with phase 1 safety demonstrated.

DD-A279

Alzheimer's therapy

Presented as a non-oncology pipeline targeting brain endotoxin and neuroinflammation.

3. Governance: from owner leadership to system management

Official fact: The source says the December 2, 2025 executive reshuffle moved chairman Jin Yang-gon out of the CEO role and toward the board-chair function.

The source reads this not as withdrawal from management, but as a role reset focused on group strategy, M&A, affiliate synergy, and shareholder communication. Practical execution shifts to professional managers including Kim Hong-cheol, Baek Yoon-ki, and Yoon Jong-sun.

HLB management triangleClear roles across control, finance, and technology
Kim Hong-cheolHLB CEO · KOSDAQ/compliance/IR
Baek Yoon-kiHLB Life Science · CFO-style financing
Yoon Jong-sunHLB Innovation · technology strategy
Jin Yang-gonboard chair · group strategy
The structure separates regulatory response, liquidity, and follow-on pipeline execution around FDA approval.
  • Kim Hong-cheol: born in 1965, PhD in business from Soongsil University, and about 20 years at KOSDAQ Association supporting roughly 1,400 member companies.
  • Baek Yoon-ki: a finance specialist with Daewoo Group, Daewoo Capital, and Aju Capital experience; the source credits him with four CB issuances and KRW 200bn of LMR investment.
  • Yoon Jong-sun: a technology expert with a master's degree from La Trobe University and biomedical research training, positioned around Verismo CAR-T collaboration and HLB Innovation's technology strategy.

HLB professional management system and FDA retry image

4. Third FDA attempt: CMC is the issue, not the clinical data

Official fact: The source says HLB received a first CRL in May 2024 and a second CRL in March 2025. It describes both as limited to CMC issues at partner Hengrui, with no FDA objection to clinical efficacy or safety.

ItemSource figure/scheduleMeaning
First CRLMay 2024Facility deficiencies and COVID-19 travel restrictions delaying inspection
Second CRLMarch 2025Three minor CMC items including sterilization process and visual inspection protocol
CARES-310 mOS23.8 months, HR 0.64, 36% lower risk of deathKey final-analysis data for rivoceranib + camrelizumab
ComparatorsSorafenib 15.2 months, Tecentriq + Avastin 19.2 months, Imfinzi + Imjudo 16.4 monthsThe source calls it the longest survival among existing first-line liver cancer therapies
ResubmissionPlanned January 2026Likely Class 2 review if facility reinspection is needed, implying a six-month clock
DecisionAround July 2026Direct US launch readiness becomes critical immediately after approval

Interpretation: The source treats the December 2025 publication in The Lancet Oncology as academic validation of the clinical data and frames the remaining issue as production and quality-control remediation. It also cites 89% approval after resubmission for CMC-related CRLs versus 24% for clinical-defect cases.

HLB rivoceranib FDA timeline and financing image

5. LMR Partners: capital to cross the death valley

Official fact: The source says HLB raised about KRW 200bn, or USD 145m, from LMR Partners. The structure is described as BW and EB.

The funding is expected to support US commercialization marketing for rivoceranib, nationwide distribution, and follow-on clinical development including Verismo CAR-T. The source's emphasis is that HLB secured enough runway to cross the post-approval period before revenue and cash flow stabilize.

6. My conclusion: 2026 is the proof year

  • Governance: watch whether Jin's strategic leadership and professional managers' execution leadership actually fit together.
  • Portfolio: the question is whether integrated HLB operates as a broader pharma-bio group across oncology, infectious disease, and dementia therapies.
  • FDA: Lancet data and CMC remediation must translate into a January 2026 resubmission and a decision around July.

HLB's investment logic now has to be verified by schedules and data, not expectation alone. I would track the January 2026 resubmission, FDA Class 2 Review classification, Hengrui facility reinspection results, and Elevar's direct-sales readiness in that order.

Sources

Naver original